Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes

Federico Carbone, Nathalie Satta, Fabrizio Montecucco, Julien Virzi, Fabienne Burger, Aline Roth, Gloria Roversi, Carmine Tamborino, Ilaria Casetta, Silva Seraceni, Alessandro Trentini, Marina Padroni, Franco Dallegri, Patrice H. Lalive, François Mach, Enrico Fainardi, Nicolas Vuilleumier

Research output: Contribution to journalArticle

Abstract

Background: Autoantibodies to apolipoprotein A-1 (anti-ApoA-1 IgG) were shown to predict major adverse cardiovascular events and promote atherogenesis. However, their potential relationship with clinical disability and ischaemic lesion volume after acute ischaemic stroke (AIS) remains unexplored. Materials and methods: We included n = 76 patients admitted for AIS and we investigated whether baseline serum anti-ApoA-1 IgG levels could predict (i) AIS-induced clinical disability [assessed by the modified Rankin Scale (mRS)], and (ii) AIS-related ischaemic lesion volume [assessed by Computed Tomography (CT)]. We also evaluated the possible pro-apoptotic and pro-necrotic effects of anti-ApoA-1 IgG on human astrocytoma cell line (U251) using flow cytometry. Results: High levels of anti-ApoA-1 IgG were retrieved in 15·8% (12/76) of patients. Increased baseline levels of anti-ApoA-1 IgG were independently correlated with worse mRS [β = 0·364; P = 0·002; adjusted odds ratio (OR): 1·05 (95% CI 1·01–1·09); P = 0·017] and CT-assessed ischaemic lesion volume [β = 0·333; P < 0·001; adjusted OR: 1·06 (95% CI 1·01–1·12); P = 0·048] at 3 months. No difference in baseline clinical, biochemical and radiological characteristics was observed between patients with high vs. low levels of anti-ApoA-1 IgG. Incubating human astrocytoma cells with anti-ApoA-1 IgG dose dependently induced necrosis and apoptosis of U251 cells in vitro. Conclusion: Anti-ApoA-1 IgG serum levels at AIS onset are associated with poorer clinical recovery and worse brain lesion volume 3 months after AIS. These observations could be partly explained by the deleterious effect of anti-ApoA-1 IgG on human brain cell survival in vitro and may have clinical implication in the prediction of poor outcome in AIS.

Original languageEnglish
Pages (from-to)805-817
Number of pages13
JournalEuropean Journal of Clinical Investigation
Volume46
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Keywords

  • Acute ischaemic stroke
  • anti-ApoA-1 IgG
  • computed tomography
  • modified Rankin Scale

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes'. Together they form a unique fingerprint.

  • Cite this

    Carbone, F., Satta, N., Montecucco, F., Virzi, J., Burger, F., Roth, A., Roversi, G., Tamborino, C., Casetta, I., Seraceni, S., Trentini, A., Padroni, M., Dallegri, F., Lalive, P. H., Mach, F., Fainardi, E., & Vuilleumier, N. (2016). Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes. European Journal of Clinical Investigation, 46(9), 805-817. https://doi.org/10.1111/eci.12664